For example: People put on GLP-1 drugs might differ in meaningful ways from those started on SGLT-2s or DPP-4s Severity of diabetes, weight, blood pressure patterns, sleep apnea, smoking history, and other factors can be hard to capture perfectly in claims Diagnostic coding can be imperfect Follow up time was up to 18 months, not years That said, the study is large, and it tries to do the comparison thoughtfully
The drug is being studied for two conditions: obesity and metabolic dysfunction-associated steatohepatitis (MASH)
One rat study found sublingual semaglutide achieved a 5-fold higher blood concentration compared to oral administration at the same dose
After the reduction process, the resulting L-Glutathione Reduced powder is separated from the reaction mixture using various purification techniques
Conclusion SGLT2 inhibitors are established therapies for reducing HF outcomes, whereas GLP-1 receptor agonists primarily address cardiometabolic risk with uncertain direct HF benefit